Company intelligence / Profile preview

TeneoOne

Ownership: Private
Development stage: Phase 1

Overview

Interim Phase I data for lead program TNB-383B in relapsed/refractory multiple myeloma showed a promising objective response rate of up to 79% and complete response rate of up to 29% at higher doses, with median duration of response not reached at interim analysis. The therapy is notable for its potential for less frequent dosing compared to other BCMA/CD3 bispecifics[5].

Therapeutic areas: Oncology
Modalities: Bispecific antibodies (notably Human Heavy Chain Antibodies/UniAbs)
Industry: Biotech

Drug pipeline

1 asset

TNB-383B

Phase 1

Indications: Multiple myeloma, Relapsed/refractory multiple myeloma

Partnerships

AbbVie Inc. (strategic partnership and subsequent acquirer)[7]

Beyond the preview

Go deeper on TeneoOne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TeneoOne.

Explore the full profile